Home Drug IndexClinical Monograph

Sodium Valproate Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

Therapeutic Class

Antiepileptic

Subclass

Broad-spectrum anticonvulsant (valproate group)

Speciality

Neurology

Schedule (India)

Schedule H

Routes

Oral, Intravenous

Formulations

Oral tablets: 200 mg, 300 mg, 500 mg
Oral controlled-release tablets: 200 mg CR, 300 mg CR, 500 mg CR
Oral syrup: 200 mg/5 mL
Injection (IV): 100 mg/mL (5 mL vial = 500 mg)
Note: Valproate semisodium (divalproex sodium) also available — refer separate entry

Adult indications

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Epilepsy — Generalised and Focal Seizures

Adults:

Parameter	Recommendation
Starting dose	10–15 mg/kg/day orally in 2–3 divided doses
Titration	Increase by 5–10 mg/kg every 5–7 days based on response
Usual maintenance dose	20–30 mg/kg/day
Maximum dose	60 mg/kg/day (specialist supervision for refractory cases)

Clinical notes:

CR formulations preferred for once or twice daily dosing and improved tolerability
Target therapeutic plasma level: 50–100 μg/mL
Syrup formulation useful for dose flexibility

2. Status Epilepticus (IV) — When first-line agents fail

Adults:

Parameter	Recommendation
Loading dose	20–40 mg/kg IV over 10–15 minutes
Maintenance	1–2 mg/kg/hour continuous infusion OR transition to oral when feasible
Maximum infusion rate	6 mg/kg/min

Clinical notes:

Specialist/ICU setting only
Avoid rapid bolus to reduce hypotension risk
Alternative when phenytoin contraindicated

3. Bipolar Disorder — Acute Mania

Adults:

Parameter	Recommendation
Starting dose	750–1000 mg/day orally in 2–3 divided doses
Titration	Increase by 250–500 mg every 3–5 days
Usual maintenance dose	1000–2000 mg/day
Maximum dose	60 mg/kg/day
Target plasma level	50–125 μg/mL

Clinical notes:

Not recommended for maintenance monotherapy in bipolar disorder
Avoid in women of childbearing potential unless pregnancy prevention programme in place

Secondary Indications — Adults Only (Off-label)

Indication	Dose	Duration	Notes
Migraine prophylaxis — OFF-LABEL	500–1000 mg/day in divided doses	3–6 months trial	Specialist initiation; supported by RCT evidence; avoid in women of childbearing age
Behavioural disturbance in dementia — OFF-LABEL	250–500 mg/day	Variable	Specialist-only; limited evidence; use with extreme caution in frail elderly

Paediatric indications

PAEDIATRIC DOSING (Specialist Only)

Primary Indications

1. Epilepsy — Generalised and Focal Seizures

Age: ≥1 month

Weight	Starting Dose	Maintenance Dose	Maximum Dose
<20 kg	10–15 mg/kg/day in 2–3 divided doses	20–30 mg/kg/day	40 mg/kg/day
≥20 kg	300–600 mg/day in 2–3 divided doses	20–35 mg/kg/day	60 mg/kg/day (refractory cases)

Clinical notes:

Use syrup formulation for accurate dosing in infants and young children
Titrate by 5–10 mg/kg/week
Target plasma levels: 50–100 μg/mL

2. Status Epilepticus (IV)

Paediatric Neurologist supervision mandatory

Parameter	Recommendation
Loading dose	20–30 mg/kg IV over 10–15 minutes
Maintenance	1–2 mg/kg/hour IV OR transition to oral

Secondary Indications — Paediatrics (Off-label)

Not routinely recommended for off-label indications in paediatric population.

Paediatric Safety Alert

⚠️ Avoid use in children <2 years unless absolutely essential and under specialist supervision — significantly increased risk of fatal hepatotoxicity, particularly with:

Polytherapy with other antiepileptics
Underlying metabolic disorders
Developmental delay

Renal Adjustments

Renal Function	Recommendation
Mild–Moderate impairment	No dosage adjustment required
Severe impairment/Dialysis	Monitor free (unbound) valproate levels; total levels may be misleading due to decreased protein binding
Haemodialysis	Valproate is not significantly dialysed; supplemental dosing generally not required

Hepatic adjustment

Contraindications

Active liver disease or significant hepatic dysfunction
Family history of severe hepatic dysfunction (especially drug-related)
Known hypersensitivity to valproate or any excipient
Urea cycle disorders (risk of hyperammonaemic encephalopathy)
Known mitochondrial disorders caused by POLG mutations
Porphyria
Women of childbearing potential for psychiatric indications or migraine (unless adequate contraception and informed consent)

Cautions

Age <2 years — highest risk of fatal hepatotoxicity
Concomitant use with other antiepileptics (increased hepatotoxicity and ADR risk)
Elderly — increased sensitivity, fall risk, cognitive effects
Pre-existing thrombocytopenia or bleeding disorders
History of pancreatitis
Systemic lupus erythematosus
Renal impairment (monitor free drug levels)
Patients at risk of suicidal ideation — monitor closely
Before elective surgery — assess bleeding risk

Pregnancy'

Aspect	Guidance
Overall risk	High teratogenic potential — neural tube defects (1–2%), craniofacial abnormalities, developmental delay, autism spectrum disorder
Epilepsy indication	Avoid if safer alternatives exist; if essential, use lowest effective dose as monotherapy (preferably <1000 mg/day)
Psychiatric/Migraine indication	CONTRAINDICATED
Preconception	High-dose folic acid (5 mg/day) at least 3 months prior
Monitoring	Detailed anomaly scan at 18–20 weeks; serial growth scans
Counselling	Mandatory informed consent regarding teratogenic risks before initiating in any woman of childbearing potential

Lactation

Aspect	Guidance
Compatibility	Generally compatible with breastfeeding
Excretion in milk	Low (1–10% of maternal serum concentration)
Infant monitoring	Observe for excessive sedation, poor feeding, jaundice
Preferred alternative	If mother requires valproate for epilepsy, breastfeeding acceptable with monitoring

Elderly

Aspect	Recommendation
Starting dose	250–500 mg/day
Titration	Slow (increase every 5–7 days)
Cautions	Increased risk of sedation, tremor, gait instability, falls
Monitoring	Baseline and periodic LFTs, platelet count; monitor for encephalopathy symptoms
Special considerations	Risk of SIADH-like hyponatraemia (rare); cognitive impairment may be exacerbated

Major drug interactions

Interacting Drug	Effect	Management
Lamotrigine	Valproate inhibits lamotrigine metabolism — markedly increased lamotrigine levels and risk of serious rash (SJS/TEN)	Reduce lamotrigine dose by 50%
Carbapenem antibiotics (meropenem, imipenem)	Rapid and significant reduction in valproate levels (up to 60–90%)	Avoid combination; use alternative antibiotic or AED
Topiramate	Additive risk of hyperammonaemia and encephalopathy	Monitor ammonia levels; avoid if possible
Phenytoin	Mutual interaction — unpredictable changes in levels of both	Monitor levels of both drugs; dose adjustment likely needed
Carbamazepine	Enzyme induction decreases valproate levels	May need to increase valproate dose; monitor levels
Warfarin	Valproate displaces warfarin from protein binding — increased bleeding risk	Monitor INR closely; adjust warfarin dose

Moderate drug interactions

Interacting Drug	Effect	Management
Aspirin (high-dose)	Increased free valproate fraction; increased toxicity risk	Use with caution, especially in children
Benzodiazepines	Additive CNS depression	Monitor for excessive sedation
Rifampicin	May reduce valproate efficacy via enzyme induction	Monitor clinical response and serum levels
Cholestyramine	Reduced valproate absorption	Separate administration by at least 3 hours
Cimetidine	Inhibits valproate metabolism; increased levels	Monitor for toxicity
Erythromycin	May increase valproate levels	Monitor

Common Adverse effects

Nausea, vomiting, dyspepsia
Weight gain
Tremor (dose-related)
Transient hair loss (reversible on dose reduction)
Drowsiness, lethargy
Asymptomatic elevation of liver transaminases
Peripheral oedema

Serious Adverse effects

Adverse Effect	Clinical Notes
Hepatotoxicity	Highest risk in children <2 years, polytherapy, metabolic disorders; can be fatal; monitor LFTs; discontinue if symptomatic liver dysfunction
Pancreatitis	Can occur at any time; may be fatal; discontinue immediately if suspected
Thrombocytopenia	Dose-related; check platelet count if bruising or bleeding
Hyperammonaemic encephalopathy	Altered consciousness, lethargy, vomiting; can occur without LFT abnormalities; check ammonia levels
Severe cutaneous reactions	SJS/TEN (rare); discontinue immediately
Teratogenicity	Neural tube defects, developmental delay — see Pregnancy section

Monitoring requirements

Phase	Parameters
Baseline	LFTs, CBC with platelets, serum ammonia (if symptoms), coagulation profile, pregnancy test (if applicable)
During titration	LFTs and CBC at 2–4 weeks
Therapeutic drug monitoring	Target: 50–100 μg/mL (epilepsy); 50–125 μg/mL (mania); check if toxicity suspected, non-response, or drug interactions
Long-term	LFTs and CBC every 3–6 months
Special populations	More frequent monitoring in children <2 years, elderly, hepatic impairment

Brands in India

Encorate®, Encorate Chrono® (Sun Pharma)
Valparin®, Valparin Chrono® (Sanofi)
Epilex®, Epilex Chrono® (Abbott)
Valance® (Intas)
Sodival® (Micro Labs)
Multiple generic formulations widely available

Price range (INR)

Formulation	Approximate Price
Tablets 200 mg	₹2–4 per tablet
Tablets 500 mg	₹4–8 per tablet
CR tablets 300 mg	₹5–10 per tablet
CR tablets 500 mg	₹8–15 per tablet
Syrup 200 mg/5 mL (100 mL)	₹25–50 per bottle
Injection 500 mg/5 mL	₹60–120 per vial

Note: Not currently on NLEM 2022 for psychiatric indications; included for epilepsy.

Clinical pearls

Hepatotoxicity risk is highest in children <2 years on polytherapy — avoid unless no alternatives; monitor LFTs rigorously
Mandatory pregnancy counselling — all women of childbearing potential must be counselled about teratogenic risks before initiation; document informed consent
CR formulations improve compliance and reduce peak-related adverse effects (tremor, sedation)
Tremor and hair loss are dose-dependent — often improve with dose reduction or zinc supplementation (for hair loss)
IV valproate is a useful second-line agent in status epilepticus when phenytoin is contraindicated (cardiac disease, hypotension)
Avoid carbapenem antibiotics in patients on valproate — dramatic reduction in levels can precipitate seizures
Check ammonia levels if unexplained lethargy or confusion develops, even with normal LFTs

Version

RxIndia v1.0 — 04 May 2025

Reference

CDSCO approved prescribing information
National Formulary of India (NFI) 2021
Indian Epilepsy Society Guidelines
NIMHANS Psychiatry Protocols
API Textbook of Medicine
AIIMS Neurology Protocols
IAP Guidelines (Paediatric dosing)
ICMR Guidelines for Reproductive Health (teratogenicity)
Published RCTs/meta-analyses (migraine prophylaxis — off-label basis)

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...